Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Is Rosario Tijeras Season 5 Renewed? Release Date, Cast, and Synopsis
The popular Mexican television series or opera drama, Rosario Tijeras, is returning for its 5th season after getting a positive...
Pokémon Horizons Season 3: Release Date, Trailer, and Spoiler
Fan of the Pokémon series and desperately waiting for its release? Good News! Pokémon Horizons Season 3 is coming up...
Drew Carey Blast on Mayor Candidate, Spencer Pratt, called him a ‘Serial Scammer’
Drew Carey, a popular host, actor, and producer, has slammed the Los Angeles mayoral candidate, Spencer Pratt. On May 24,...
15+ Best Thrillers on Netflix: Movies and Television Series
Do you love to watch thriller shows and movies? Here, in this blog, I have mentioned the best thrillers on...
Maternal Instinct: A True Crime Documentary will release on Netflix this June
Do you also like true crime documentaries like The Investigation of Lucy Letby and Should I Marry a Murderer? Good...
You Can’t Skip These Roblox Competitors
Roblox has introduced millions of joystick junkies and developers to the world for creating amazing games and igniting their creative...